EUVIMEDEUVIMED entdecken
Beobachtungsstudie

The Efficacy and Safety of Hepatitis A Vaccine in Children and Young Adults With an Autoinflammatory Diseases on Canakinumab and Tocilizumab Treatments: A Prospective Observational Controlled Study

Kenan Barut iD, Mehmet Yildiz iD, Ömer Faruk Beşer, Fatih Haslak iD, Aybuke Gunalp iD, Elif Kılıç Konte iD, Esma Aslan iD, Ümit Gül iD, Nergis Akay iD, Amra Adrovic iD, Sezgin Sahin iD, Pelin Yüksel Mayda iD und 2 weitere

International Journal of Rheumatic Diseases · 2025

DOI: 10.1111/1756-185x.70196 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Rheumatic Diseases, 2025. Verfasst von Kenan Barut und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Rheumatology, İstanbul University-Cerrahpaşa Cerrahpaşa, İstanbul, Turkey. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Arthritis, Juvenile, Hepatitis A Vaccines, Cryopyrin-Associated Periodic Syndromes. Die Arbeit nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Intro In this prospective interventional study, we aimed to assess the efficacy and safety of the hepatitis A vaccine in patients with autoinflammatory diseases undergoing canakinumab and tocilizumab treatments.

Methods

A total of 24 patients with autoinflammatory diseases on canakinumab and tocilizumab treatments and 39 healthy children who were seronegative for hepatitis A were included in the study. All participants were vaccinated with 2 doses of inactivated hepatitis A vaccine at 6‐month intervals. One month after the last vaccination, venous blood samples were collected from each participant, and the anti‐HAV IgM and IgG titers were measured.

Results

The patient group consisted of 19 patients with systemic juvenile idiopathic arthritis (sJIA) and 5 patients with cryopyrin‐associated periodic fever. The mean age of the patient group and the healthy controls were 14.1 ± 3.7 and 12.4 ± 3.2 years, respectively. All patients with cryopyrin‐associated periodic fever and 52.6% (10/19) of the patients with sJIA were on canakinumab. The remaining 9 patients (47.3%) with sJIA were using tocilizumab. Among sJIA patients, 15 were also on methotrexate, and 14 were on prednisolone. All of the participants were negative for hepatitis A serology. After two doses of hepatitis A vaccine, all the patients with autoinflammatory diseases (24/24) and 84.6% (33/39) of the healthy controls were detected as positive for anti‐HAV IgG ( p = 0.04). The mean anti‐HAV Ig G titers of the patient group and the control group one month after the last dose of vaccination were 5.25 ± 1.49 IU/L and 10.5 ± 7.02 IU/L, respectively ( p < 0.001). Neither disease flares nor adverse effects related to vaccination were observed within the study period.

Conclusion

Hepatitis A vaccine is effective and safe in children with autoinflammatory diseases on biologic therapy. Long‐term follow‐up data, including larger patient cohorts, are needed to draw a solid conclusion about the safety of hepatitis A vaccine in patients receiving canakinumab and tocilizumab therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedArthritis, JuvenileHepatitis A VaccinesCryopyrin-Associated Periodic SyndromesHepatitis AHereditary Autoinflammatory DiseasesImmunosuppressive AgentsHumansProspective StudiesMaleFemaleChildTreatment OutcomeAdolescentYoung AdultTime FactorsHepatitis A AntibodiesAge FactorsCase-Control Studies

Stichwörter der Autor:innen

Cryopyrin‐associated periodic syndromeanti‐IL1anti‐IL6autoinflammatory diseasescanakinumabfamilial Mediterranean feverhepatitis a vaccinesystemic juvenile idiopathic arthritistocilizumab

Substanzen

canakinumabtocilizumabAntibodies, Monoclonal, HumanizedHepatitis A VaccinesHepatitis A AntibodiesImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Pediatric Rheumatology, İstanbul University-Cerrahpaşa Cerrahpaşa, İstanbul, Turkey.
  • Department of Pediatric Gastroenterology, Hepatology, and Nutrition, İstanbul University-Cerrahpaşa Cerrahpaşa, İstanbul, Turkey.
  • Kocaeli Health and Technology University, Faculty of Pharmacy, Kocaeli, Turkey.
  • İstanbul University-Cerrahpaşa Cerrahpaşa, Department of Medical Microbiology, İstanbul, Turkey.

ORCID-Profile: Kenan Barut, Mehmet Yildiz, Fatih Haslak, Aybuke Gunalp, Elif Kılıç Konte, Esma Aslan, Ümit Gül, Nergis Akay, Amra Adrovic, Sezgin Sahin, Pelin Yüksel Mayda, Özgür Kasapçopur

Zitieren

APA

Barut, K., Yildiz, M., Beşer, Ö. F., Haslak, F., Gunalp, A., Konte, E. K., Aslan, E., Gül, Ü., Akay, N., Adrovic, A., Sahin, S., Mayda, P. Y., Kocazeybek, B., & Kasapçopur, Ö. (2025). The Efficacy and Safety of Hepatitis A Vaccine in Children and Young Adults With an Autoinflammatory Diseases on Canakinumab and Tocilizumab Treatments: A Prospective Observational Controlled Study. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70196

Vancouver

Barut K, Yildiz M, Beşer ÖF, Haslak F, Gunalp A, Konte EK, et al. The Efficacy and Safety of Hepatitis A Vaccine in Children and Young Adults With an Autoinflammatory Diseases on Canakinumab and Tocilizumab Treatments: A Prospective Observational Controlled Study. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70196

BibTeX
@article{Barut2025,
  author = {Barut, Kenan and Yildiz, Mehmet and Beşer, Ömer Faruk and Haslak, Fatih and Gunalp, Aybuke and Konte, Elif Kılıç and Aslan, Esma and Gül, Ümit and Akay, Nergis and Adrovic, Amra and Sahin, Sezgin and Mayda, Pelin Yüksel and Kocazeybek, Bekir and Kasapçopur, Özgür},
  title = {The Efficacy and Safety of Hepatitis A Vaccine in Children and Young Adults With an Autoinflammatory Diseases on Canakinumab and Tocilizumab Treatments: A Prospective Observational Controlled Study},
  journal = {International Journal of Rheumatic Diseases},
  year = {2025},
  doi = {10.1111/1756-185x.70196}
}
Kostenlos starten →